– Record Quarterly Revenue of $148.3 million – – Quarterly Operating Profit of $17.4 million – – Quarterly Net Income of $8.1 million – – Quarterly Adjusted EBITDA1 of $30.3 million – – Record Backlog and Awarded Orders of $747.6 million – – Provides First Quarter and Full Year 2026 Outlook – PORTLAND, Tenn., Feb. 24, 2026 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a leading provider of electrical balance of system (“EBOS”) solutions and components, including battery energy storage solutions (“BESS”), and Original Equipment Manufacturer (“OEM”) components for the global energy transition market, today announced results for its fourth quarter ended December 31, 2025. “2025 was an exceptional year for Shoals. While the rapidly shifting political climate brought some volatility,...

~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in Second-Line Advanced Non-Small Cell Lung Cancer SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported fourth quarter and full year 2025 financial results, business achievements and corporate updates. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, “Iovance delivered approximately 30 percent quarterly revenue growth and achieved our 2025 guidance range in the first...

Fourth quarter revenues totaled $556 million Fourth quarter GAAP consolidated loss from continuing operations of $86 million, including expenses related to the pending sale of Clean Earth and spin-off of Harsco Environmental and Harsco Rail as well as certain contract adjustments in Harsco Rail Adjusted EBITDA in Q4 totaled $70 million Full year 2025 revenue totaled $2.2 billion; GAAP consolidated loss from continuing operations was $160 million; and Adjusted EBITDA totaled $275 million 2026 outlook: Adjusted EBITDA for Harsco Environmental and Harsco Rail (“New Enviri”) expected to be modestly below 2025 at guidance mid-point, as improvement in Harsco Environmental to be offset by Harsco RailPHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) — Enviri Corporation (NYSE: NVRI) (the “Company”) today reported...

ALACHUA, Fla. and TAMPA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter Financial ResultsFourth quarter 2025 revenue was $59.9 million, a 21.3% increase compared to the fourth quarter 2024 revenue, and a 0.3% decrease over the third quarter 2025 revenue.Fourth quarter 2025 gross margin was 74.1%, down from 76.1% for the fourth quarter of 2024, and down from 76.6% in the third quarter of 2025.Gross margin reflects one-time costs of approximately $1.9 million, or 3% for the fourth quarter of 2025, related to the U.S. Food and Drug Administration (“FDA”)...

Rebrands to Cipher Digital to Reflect Strategic Shift Toward HPC Divested 49% Stake in Alborz, Bear, and Chief Mining Sites Secured Full Funding for Existing Data Center Developments Through High-Yield Bond Offerings Data Center Development on Track at Barber Lake and Black Pearl NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) — Cipher Digital Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”) today announced its fourth quarter and full year 2025 financial results, with an update on its operations and business strategy. “Building on a transformative 2025, the fourth quarter reflected continued momentum as we advanced our evolution into a leading HPC data center development company,” said Tyler Page, Chief Executive Officer. “During the quarter, we upsized our initial lease with Fluidstack and Google and signed our first HPC lease with Amazon....

BANNOCKBURN, Ill., Feb. 24, 2026 (GLOBE NEWSWIRE) — Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights (year-over-year comparisons unless otherwise noted)Net revenue of $1,465.4 million, up 8.8% Net income of $58.5 million, down 2.7% GAAP diluted earnings per share of $0.37, up 5.7% Adjusted EBITDA of $126.0 million, up 3.7% Adjusted diluted earnings per share of $0.46, up 4.5% Repurchased $95 million of stock in the quarterFull Year 2025 Financial Highlights (year-over-year comparisons unless otherwise noted)Net revenue of $5,649.5 million, up 13.0% Net income of $207.6...

– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – – ARV-102 (LRRK2) Phase 1 clinical data in patients with Parkinson’s disease accepted for oral presentation at AP/PD Conference in March 2026 – – Clinical data from ARV-806 (KRAS G12D) and ARV-393 (BCL6) on track for presentations in 2026 – – Phase 1 trial in healthy volunteers initiated with polyQ-AR degrader ARV-027; first immuno-oncology PROTAC HPK1 degrader, ARV-6723, on track to initiate Phase 1 trial in mid-2026 – – Randy Teel, Ph.D., appointed President, Chief Executive Officer, and Director – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN),...

Q4 revenue increased 30% year-over-year to a record $192 million, driven by robust marketplace growth. Q4 marketplace revenue growth accelerated to 33% year-over-year, driven by strong enterprise growth and expanded networks of buyers and suppliers. Q4 gross profit increased 27% year-over-year to a record $75.2 million, driven by strong marketplace growth and marketplace gross margin expansion. Q4 Adjusted EBITDA improved $7.3 million year-over-year to Adjusted EBITDA of $8.4 million, driven by expanding marketplace gross margin and strong operating expense leverage. Strong operating results were driven by consistent execution across growth initiatives: expanding buyer and supplier networks, driving deeper enterprise engagement, further expanding the marketplace platform, growing internationally, and enhancing services offerings.NORTH...

Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 million EMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102 millionRegulatory submission for SYFOVRE prefilled syringe planned for the first half of 2026 EMPAVELI franchise has strong momentum with successful launch in C3G and primary IC-MPGN, and pivotal trials underway in FSGS and DGF Cash and cash equivalents of $466 million as of December 31, 2025; projected revenues, cash, and cash equivalents expected to be sufficient to fund operations to profitability Management to host conference call today at 8:30 a.m. ETWALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its fourth quarter and full year 2025 financial results...

― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― 20 mg cohort demonstrated rapid and robust fetal hemoglobin (HbF) induction, with mean absolute HbF increasing by 12.2% from a baseline of 7.1% to 19.3% at Week 12, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ― ― Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026 ― ― Ended 2025 with $352.3 million in cash, cash equivalents, and marketable securities; cash runway into 2029 ― CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients...